Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors.

Zhao, X; Suryawanshi, S; Hruska, M; Feng, Y; Wang, X; Shen, J; Vezina, H E; McHenry, M B; Waxman, I M; Achanta, A; Bello, A; Roy, A; Agrawal, S

Zhao, X; Suryawanshi, S; Hruska, M; Feng, Y; Wang, X; Shen, J; Vezina, H E; McHenry, M B; Waxman, I M; Achanta, A; Bello, A; Roy, A; Agrawal, S.

Affiliation

Zhao X; Clinical Pharmacology & Pharmacometrics.
Suryawanshi S; Clinical Pharmacology & Pharmacometrics.
Hruska M; Clinical Pharmacology & Pharmacometrics.
Feng Y; Clinical Pharmacology & Pharmacometrics.
Wang X; Clinical Pharmacology & Pharmacometrics.
Shen J; Clinical Pharmacology & Pharmacometrics.
Vezina HE; Clinical Pharmacology & Pharmacometrics.
McHenry MB; Global Biometric Sciences.
Waxman IM; Oncology Clinical Development.
Achanta A; Global Regulatory Sciences, Global Biometric Sciences, Bristol-Myers Squibb, Princeton, NJ, USA.
Bello A; Clinical Pharmacology & Pharmacometrics.
Roy A; Clinical Pharmacology & Pharmacometrics.
Agrawal S; Clinical Pharmacology & Pharmacometrics.

Ann Oncol ; 28(8): 2002-2008, 2017 Aug 01.

Article de En | MEDLINE | ID: mdl-28520840

Sujet(s)
Mots clés

cancer immunotherapy; clinical pharmacology; exposureresponse relationship; flat dosing; nivolumab; solid tumors

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Anticorps monoclonaux / Tumeurs / Antinéoplasiques Type d'étude: Etiology_studies / Prognostic_studies / Risk_factors_studies Limites: Humans Langue: En Journal: Ann Oncol Sujet du journal: NEOPLASIAS Année: 2017 Type de document: Article Pays de publication: Royaume-Uni

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google